Netanel Eisenbach

Dr. Netanel Eisenbach

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in European Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
ADAmiel Dror
Amiel Dror
NENetanel Eisenbach
Netanel Eisenbach
STShahar Taiber
Shahar Taiber
NMNicole G. Morozov
Nicole G. Morozov
MMMatti Mizrachi
Matti Mizrachi
ESEyal Sela
Eyal Sela

29 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
RCRaisa Chowdhury
Raisa Chowdhury
JHJessica Hier
Jessica Hier
KPKayla Payne
Kayla Payne
MAMawaddah Abdulhaleem
Mawaddah Abdulhaleem
ODOrr Dimitstein
Orr Dimitstein
RPRichard Payne
Richard Payne
Background: The management of indeterminate thyroid nodules (Bethesda III/IV) has evolved with molecular testing, aiming to reduce unnecessary surgeries. However, the comparative effectiveness of different platforms in influencing surgical decision-making remains unclear. This systematic review and meta-analysis evaluate the impact of molecular testing on surgical avoidance rates. Methods: A systematic literature search was conducted across eight electronic databases, including Embase, PubMed, and Cochrane Library, from January 2019 to December 2024, following PRISMA guidelines to encompass most recent advancements in the last 5 years. Studies evaluating Afirma Gene Expression Classifier (GEC), Afirma Genomic Sequencing Classifier (GSC), ThyroSeq V2, ThyroSeq V3, and ThyGenX/ThyraMIR were included. The primary outcome was surgical avoidance, analyzed using a random-effects model. Results: Thirty-one studies comprising 4464 indeterminate thyroid nodules met inclusion criteria. Pooled surgical avoidance rates varied across platforms: ThyroSeq V2 (50.3%, 95% CI: 20.8–79.6%), ThyroSeq V3 (62.5%, 95% CI: 54.8–70.0%), Afirma GEC (58.8%, 95% CI: 43.6–73.1%), Afirma GSC (50.6%, 95% CI: 34.3–66.8%), and ThyGenX/ThyraMIR (68.6%, 95% CI: 63.1–73.9%). ThyGenX/ThyraMIR had the highest surgical avoidance rate and lowest heterogeneity (I2 = 51.2%), while ThyroSeq showed improvement from V2 to V3. Conclusions: Molecular testing reduces unnecessary thyroid surgeries, with avoidance rates ranging from 50.3% to 68.6%. While ThyGenX/ThyraMIR showed the highest avoidance rate, its limited representation warrants cautious interpretation. Standardized protocols are needed to optimize clinical application. Further prospective studies should compare platforms and assess long-term outcomes and cost-effectiveness.

22 January 2020 in Clinical Otolaryngology
Verified
Journal Article
Closed access
PDF file
NENetanel Eisenbach
Netanel Eisenbach
SMSofi Matot
Sofi Matot
ANAchia Nemet
Achia Nemet
ESEyal Sela
Eyal Sela
TMTal Marshak
Tal Marshak
OROhad Ronen
Ohad Ronen

6 August 2020 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
NENetanel Eisenbach
Netanel Eisenbach
OKOhad Karni
Ohad Karni
ESEyal Sela
Eyal Sela
ANAchia Nemet
Achia Nemet
ADAmiel Dror
Amiel Dror
TMTal Marshak
Tal Marshak

12 May 2020 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
YSYair Heskiau Shteinberg
Yair Heskiau Shteinberg
NENetanel Eisenbach
Netanel Eisenbach
ESEyal Sela
Eyal Sela
MGMaayan Gruber
Maayan Gruber
OROhad Ronen
Ohad Ronen

1 October 2018 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
FJF. Jahshan
F. Jahshan
OEOffir Ertracht
Offir Ertracht
Aiman Abu AmmarAiman Abu Ammar
Aiman Abu Ammar
ORO. Ronen
O. Ronen
SSSamer Srouji
Samer Srouji
MGM. Gruber
M. Gruber